VERAXA Biotech (NASDAQ: VRXA) has announced that it has received Scientific Advice from Germany's Paul-Ehrlich-Institute (PEI), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead BiTAC®-TCE program. The announcement, released on July 20, marks a significant milestone as the company advances its proprietary bispecific T-cell engager platform toward clinical development. The PEI's guidance is expected to reduce development uncertainty by offering greater clarity on safety assessments and non-clinical plans before the company initiates clinical studies.
The BiTAC®-TCE platform is designed to harness the immune system to target and eliminate cancer cells. VERAXA's lead candidate has previously demonstrated encouraging preclinical data, which was presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The regulatory feedback from the PEI, one of Europe's leading regulatory authorities, provides early validation of the company's approach and helps align its development strategy with regulatory expectations.
Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies address potential issues related to safety, tolerability, and efficacy. According to VERAXA, the PEI's input supports the biological rationale and safety assessments for the BiTAC®-TCE program, which could streamline the path to clinical trials. The company believes that this guidance mitigates risks associated with early-stage development and enhances the likelihood of successful regulatory submissions.
In addition to the BiTAC®-TCE platform, VERAXA is building a diversified oncology pipeline that includes antibody-drug conjugates (ADCs) and other engineered antibody formats. The company continues to make progress in manufacturing and development as it advances next-generation antibody therapeutics for cancer. This latest regulatory milestone follows a series of positive developments, including the preclinical data presented at AACR and ongoing manufacturing advancements.
For more information about VERAXA Biotech and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
